LAS VEGAS, June 8, 2009 (GLOBE NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO) believes that a breast cancer patient treated with its Contura(tm) Multi-Lumen Balloon (MLB) receives a more targeted dose of radiation while minimizing radiation to healthy surrounding tissue such as the skin and ribs than those treated with whole breast irradiation or with a single-lumen balloon. A growing and compelling body of scientific data suggests SenoRx is right.
Over the past few months data has been rolling in from experts and opinion leaders, research partners and clinical sites. A consensus is forming and the future for Contura MLB (and SenoRx) seems brighter than ever.
For the record, SenoRx received 510(k) clearance from the U.S. Food and Drug Administration on May 23, 2007 for Contura, a specialized catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. Contura MLB is one of a new class of devices which may reduce treatment time to five days from six to eight weeks for some patients. SenoRx was quick to commercialize the innovative device domestically and has initiated plans for a European roll-out as well. Contura sales growth has been strong, increasing sequentially by more than 30 percent in each of the last three quarters.
There is a growing body of positive clinical evidence on Contura MLB. Notably, two peer-reviewed journal articles summarizing clinical findings related to Contura MLB have been published or are pending publication. These and other studies strengthen and support SenoRx's claim that an appropriately selected patient treated with Contura MLB receives a more targeted dose of radiation, while minimizing radiation to healthy surrounding tissue. This breakthrough has allowed for more patients to be treated with Contura MLB who previously may not have been candidates for accelerated partial breast radiation therapy. The first article was published in Brachytherapy and the second has been accepted for publication in The American Surgeon. Additionally, since the beginning of 2009 alone, eight additional abstracts have been presented or are scheduled for presentation at major industry meetings.
Now, SenoRx has announced that three oral presentations summarizing clinical findings related to Contura MLB was delivered at the American Brachytherapy Society Annual Meeting on May 31 through June 2, 2009 in Toronto, Canada. These presentations at the ABS meeting provide SenoRx with an opportunity for Contura MLB's successes to be detailed to a well-suited constituency of key opinion leaders from major universities and institutions involved in the field of brachytherapy.
Moreover, SenoRx already has 30 participating sites in the Contura MLB Registry Study with 156 patients presently enrolled. The data back from these studies may further add to an already growing body of evidence.
For an Integrity Media profile of SenoRx please visit: www.IntegrityIR.com/SENO
The Irvine, California based medical device company develops, manufactures, and sells minimally invasive devices for the diagnosis and treatment of breast cancer and is a rapidly growing participant in the medical device market which includes Endologix, Inc. (Nasdaq:ELGX), Micrus Endovascular Corporation (Nasdaq:MEND), Vascular Solutions, Inc. (Nasdaq:VASC), VNUS(r) Medical Technologies, Inc. (Nasdaq:VNUS), and Volcano Corporation (Nasdaq:VOLC).
Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. Small Cap Sentinel is property of Integrity Media Inc. (IMI). IMI provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies haven't always approved the statements made in this report. This report is neither a solicitation to buy nor offer to sell securities and is for information purposes only and should not be used as basis for investment decisions. IMI isn't an investment advisor, analyst or licensed broker dealer and this report isn't investment advice. IMI has been paid thirty-thousand dollars by SenoRx for this report and other services to be performed over the remainder of the calendar year. Paid reports constitute a conflict of interest as to IMI's ability to remain objective in communication regarding subject companies.